ロード中...
Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistan...
保存先:
| 出版年: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5980577/ https://ncbi.nlm.nih.gov/pubmed/29468841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12289 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|